ReN 1820

Drug Profile

ReN 1820

Alternative Names: TrkAd5

Latest Information Update: 21 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Bristol
  • Developer ReNeuron
  • Class Anti-inflammatories
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Interstitial cystitis

Most Recent Events

  • 21 Jul 2006 ReN 1820 is available for outlicensing (
  • 21 Jul 2006 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 21 Jul 2006 Discontinued - Preclinical for Interstitial cystitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top